Evaluation of the Therapeutic Approach and Outcome of Type 2 Diabetes Mellitus Management Strategies in Cameroon

Main Article Content

Lukong Marie Chantal Suinyuy
Tembe Estella Fokunang
Dehayen Mesmin
Ngo Valery Ngo
Charles Ntungwen Fokunang


Introduction: Type 2 diabetes mellitus (T2DM) is a metabolic syndrome that is characterized by chronic hyperglycaemia, and can lead to chronic long-term complications. The prevalence of diabetes mellitus in Cameroon has been reported at 5.9% in 2017. Studies conducted in 2011, showed that only 41% of patients had a good glycaemic control which was, HbA1c < 6.5.

The aim of this study was therefore to evaluate the treatment intensification with time in T2DM patients in the Yaoundé diabetic Centre in Cameroon.

Methods: The study was a cross-sectional analytical study. In a group of T2DM patients followed up at the National Obesity Centre (NOC) with poorly controlled blood sugar (HbA1c ≥ 7%). The treatment intensification and outcome were evaluated between the periods January 2016 to April 2018. The data was collected from patients’ medical booklet and through a face-to-face interviewer-administered questionnaire.

Results: One hundred and eleven patients (31 males, 27.9% and 80 females, 72.1%) were recruited. The mean age was between 59 ± 10 years and the mean duration of diabetes 8.6 ± 7.0 years. The patients’ treatment consisted: 1) oral anti-diabetic (OAD) agents, monotherapy (24.3%), bitherapy (28.8%), tritherapy 2.7%, 2) insulin only, 19.8% and 3) insulin mixture, 24.3%. The mean baseline HbA1c was 9.3 ± 2.0%. Within the given follow-up time of 16 [11-21] months, only 40 out of the 111 patients had their treatment intensified and 71 had no intensification (therapeutic inertia) despite poor HbA1c levels. Among the 40 with intensification, 5 had immediate intensification and the proportions according to intensification delay ≤3 months, 3-6 months, 6-12 months and >12 months .

Conclusion:     Therapeutic inertia affected two third of our population. Despite the high level of inertia, both patients with intensified treatment and non-intensified treatment reached treatment targets.

Type 2 diabetes mellitus, glycated haemoglobin, treatment intensification, therapeutic inertia.

Article Details

How to Cite
Suinyuy, L. M., Fokunang, T., Mesmin, D., Ngo, N., & Fokunang, C. (2019). Evaluation of the Therapeutic Approach and Outcome of Type 2 Diabetes Mellitus Management Strategies in Cameroon. Journal of Advances in Medical and Pharmaceutical Sciences, 20(4), 1-15. https://doi.org/10.9734/jamps/2019/v20i430115
Original Research Article

Article Metrics


World Health Organisation. Screening for Type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. Geneva. 2003;54. Report No. 03.1.

International Diabetes Federation. International Diabetes Federation. IDF Diabetes Atlas [Internet]. 8th edn. Brussels, Belgium. 2017;145.
Available: www.diabetesatlas.org

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care [Internet]. 2006;29(8):1963–72.
[Cited 2017 Nov 28]

Cheng AYY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. Can Med Assoc J [Internet]. 2005;172(2):213–26.
[Cited 2018 Apr 19]

International Diabetes Federation. Global Guideline for Type 2 Diabetes. Clinical Guidelines Task Force [Internet]. Brussels, Belgium; 2012; 109 .
[Cited 2017 Nov 14]
Available: www.idf.org

American Diabetes Association. Standards of medical care in diabetes 2017. Clinical and Applied Research and Education [Internet]. 2017;40.

Czupryniak L. Guidelines for the management of type 2 diabetes: Is ADA and EASD consensus more clinically relevant than the IDF recommendations? Diabetes Res Clin Pract [Internet]. 2009; ;86(S1):S22–5.
[Cited 2017 Nov 25]

Grant RW, Wexler DJ, Watson AJ, Lester WT, Cagliero E, Campbell EG, Nathan DM. How doctors choose medications to treat type 2 diabetes. Diabetes Care [Internet]. 2007;30(6).
[Cited 2018 Jan 2]

Sobngwi E, Ndour-Mbaye M, Boateng KA, Ramaiya KL, Njenga EW, Diop SN, Mbanya J-C, Ohwovoriole AE. Type 2 diabetes control and complications in specialised diabetes care centres of six sub-Saharan African countries: The Diabcare Africa study. Diabetes Res Clin Pract [Internet]. 2012;95(1):30–6.
[Cited 2017 Dec 7]

Echouffo-Tcheugui JB, Kengne AP. Chronic non-communicable diseases in Cameroon - burden, determinants and current policies. Glob Health [Internet]. 2011;7:44.
[Cited 2017 Nov 28]

Berhane Fseha. Glycemic control and it’s associated factors in type 2 diabetic patients in Suhul Hospital, Northwest Tigray, Ethiopia. J Diabetes Metab. 2017;8(3).

Govender RD, Gathiram P, Panajatovic M. Poor control and management of type 2 diabetes mellitus at an under-resourced South African Hospital: Is it a case of clinical inertia? South Afr Fam Pract [Internet]. 2017;59(5):154–9.
[Cited 2017 Dec 21]

Ziemer DC, Doyle JP, Barnes CS, Branch WT, Cook CB, El-Kebbi IM, Gallina DL, Kolm P, Rhee MK, Phillips LS. An intervention to overcome clinical inertia and improve diabetes mellitus control in a primary care setting: Improving primary care of African Americans with diabetes (IPCAAD) 8. Arch Intern Med [Internet]. 2006;166(5):507–13.
[Cited 2017 Dec 14]

Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27(7):1535–40.

Kibirige D, Atuhe D, Sebunya R, Mwebaze R. Suboptimal glycaemic and blood pressure control and screening for diabetic complications in adult ambulatory diabetic patients in Uganda: A retrospective study from a developing country. J Diabetes Metab Disord [Internet]. 2014;13:40.
[Cited 2017 Dec 7]

Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care. 2005 Mar;28(3):600–6.

Fu AZ, Qiu Y, Davies MJ, Radican L, Engel SS. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy. Diabetes Obes Metab. 2011;13(8):765–9.

World Health Organization. Tool for assessment of diabetes and diabetic retinopathy (TADDS). Geneva, Switzerland. 2015;29.

Diagnosis and classification of diabetes mellitus. Diabetes Care [Internet]. 2010;33(S1):S62–9.
[Cited 2017 Nov 28]

American Diabetes Association. Classification and diagnosis of diabetes. standards of medical care in diabetes. 2015;38.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047–53.

Sidorenkov MM, Martin M. Zdanowicz. Essentials of pathophysiology for pharmacy. Washington, D.C: CRC Press Pharmacy Education Series. 2011;203–9.

World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva, Switzerland. 2006;50.

International Diabetes Federation. Type 2 Diabetes clinical practice guidelines for sub-Saharan Africa. Africa Region. 2006; 60.

Simpson SH, Lin M, Eurich DT. Medication adherence affects risk of new diabetes complications: A cohort study. Annals of Pharmacotherapy [Internet]. 2016;17:1–16. Available:aop.sagepub.com

Perreault S, Yu AYX, Côté R, Dragomir A. Adherence to antihypertensive agents after ischemic stroke and risk of cardiovascular outcomes. American Academy of Neurology. 2012;2037–48.

Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab [Internet]. 2016;20(4):546–51.
[Cited 2017 Nov 28]

Lee PG, Halter JB. The pathophysiology of hyperglycemia in older adults: Clinical considerations. Diabetes care [Internet]. 2017;40(4):444–52.
[Cited 2018 Apr 19]

Yu-Ju Tseng, Gregory Steinberg, Kathe P. Fox, Joanne Armstrong, Kenneth D. Mand. Antihyperglycemic Medications: A claims-based estimate of first-line therapy use prior to initialization of second-line medications. Diabetes Care. 2017;40:1500–1505.

Susan Cornell. The AADE 2017 Pharmacotherapy Bootcamp. Lecture presented at: Midwestern University; 2017. Chicago College of Pharmacy.

Arun Chaudhury, Chitharanjan Duvoor, Vijaya Sena Reddy Dendi, Shashank Kraleti, Aditya Chada, Rahul Ravilla, Nawal Singh Shekhawat, Maria Theresa Montales, Kevin Kuriakose, Appalanaidu Sasapu, Alexandria Beebe, Naveen Patil, Chaitanya K. Musham, Govinda Prasad Lohani, Wasique Mirza. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol [Internet]. 2017;8(6).

Paul GH, Essien O, Otu A, Umoh V, Enang O, Hicks JP, Walley J. Intensive patient education improves glycaemic control in diabetes compared to conventional education: A randomised controlled trial in a Nigerian Tertiary Care Hospital. PLoS ONE [Internet]. 2015;12(1).
[Cited 2017 Nov 3]

DPP-4_inhibitors [TUSOM | Pharmwiki] [Internet].
[Cited 2018 May 28]

Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T, Knop FK. Effect of bile acid sequestrants on glycaemic control: Protocol for a systematic review with meta-analysis of randomised controlled trials. BMJ Open [Internet]. 2012;2(6):e001803.
[Cited 2018 Apr 19]

Tunceli IP, Malhotra A, Kudyar S, Gupta AK, Kudyar RP, Malhotra P. Sodium glucose co-transporter inhibitors – A new class of old drugs. Int J Appl Basic Med Res [Internet]. 2015;5(3):161–3.
[Cited 2018 Apr 19]

Fu OL, DeFronzo RA. Bromocriptine: A sympatholytic, D2-Dopamine agonist for the treatment of type 2 diabetes. Diabetes Care [Internet]. 2011;34(4):789–94.
[cited 2018 Apr 19]

Arthur C. Guyton, John E. Hall. Textbook of medical physiology. Eleventh edition. Philadelphia, Pennsylvania: Elsevier Suanders. 2006;961–963.

Donner T. Insulin – Pharmacology, therapeutic regimens and principles of intensive insulin therapy. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Endotext [Internet]. South Dartmouth (MA): MD Text.com, Inc; 2000
[Cited 2018 Apr 19].

Madhu S, Srivastava S. Diabetes Mellitus: Diagnosis and Management Guidelines. JIMSA. 2015;28(1):47–50.

Khunti K, Gomes MB, Pocock S, Shestakova MV, Pintat S, Fenici P, Hammar N, Medina J. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab [Internet]. [Cited 2017 Dec 6];n/a-n/a. Available:http://onlinelibrary.wiley.com/doi/10.1111/dom.13088/abstract

Mata-Cases M, Benito-Badorrey B, Roura P, Franch-Nadal J, Pepió J, Saez M, Tuero G. Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care. Curr Med Res Opin. 2013;14;29.

Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab [Internet]. 2017;43(6):501–11.
[Cited 2017 Dec 7]

O’Connor PJ, Sperl-Hillen JAM, Johnson PE, William A. Rush, George Biltz. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES, et al. editors. Advances in patient safety: From research to implementation (Volume 2: Concepts and methodology). Rockville (MD). Agency Healthc Res Qual US [Internet]. 2005;2.

Pantalone KM, Wells BJ, Chagin KM, Ejzykowicz F, Yu C, Milinovich A, Bauman JM, Kattan MW, Rajpathak S, Zimmerman RS. Intensification of diabetes therapy and time until A1C goal attainment among patients with newly diagnosed type 2 diabetes who fail metformin monotherapy within a large Integrated Health System. Diabetes Care [Internet]. 2016;39(9):1527–34.
[Cited 2017 Dec 14]

Allen JD, Curtiss FR, Fairman KA. Nonadherence, Clinical Inertia, or Therapeutic Inertia? J Manag Care Pharm [Internet]. 2009;15(8):690–5
[Cited 2017 Dec 14].

Aujoulat I, Jacquemin P, Rietzschel E, Scheen A, Tréfois P, Wens J, Darras E, Hermans MP. Factors associated with clinical inertia: An integrative review [Internet]. Advances in Medical Education and Practice; 2014.
[Cited 2017 Dec 14]

Ajmera M, Raval A, Zhou S, Wei W, Bhattacharya R, Pan C, Sambamoorthi U. A real-world observational study of time to treatment intensification among elderly patients with inadequately controlled type 2 diabetes mellitus. J Manag Care Spec Pharm [Internet]. 2015;21(12):1184–93. [Cited 2017 Dec 21]

Louise Watson, Romita Das, Ruth Farquhar, Anthony H Barnett. Consequences of delaying treatment intensification in type 2 diabetes: Evidence from a UK database. Current Medical Research and Opinion. 2016;32(9):1–39.

Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol [Internet]. 2015;14:100.
[Cited 2018 May 12]

Khunti K, Damci T, Meneghini L, Pan CY, Yale J-F. On behalf of the solve study group. Study of once daily levemir (SOLVETM): Insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice. Diabetes Obes Metab [Internet]. 2012;14(7):654–61.
[Cited 2017 Dec 14]